UTHR logo

UTHR
United Therapeutics Corp

2,497
Mkt Cap
$24.13B
Volume
334,196.00
52W High
$609.35
52W Low
$272.12
PE Ratio
20.98
UTHR Fundamentals
Price
$568.58
Prev Close
$575.79
Open
$576.49
50D MA
$560.11
Beta
0.44
Avg. Volume
470,504.76
EPS (Annual)
$27.86
P/B
4.06
Rev/Employee
$2.27M
$20,418.98
Loading...
Loading...
News
all
press releases
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the companys Investigational...
Business Wire·19h ago
News Placeholder
More News
News Placeholder
CPRX or UTHR: Which Is the Better Value Stock Right Now?
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Zacks·2d ago
News Placeholder
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease Varda Space Industries and United Therapeutics Collaborate to Advance...
PR Newswire·3d ago
News Placeholder
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from...
Business Wire·4d ago
News Placeholder
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the...
Business Wire·5d ago
News Placeholder
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.
Zacks·9d ago
News Placeholder
United Therapeutics (NASDAQ:UTHR) Announces Earnings Results, Misses Expectations By $1.18 EPS
United Therapeutics (NASDAQ:UTHR - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter...
MarketBeat·10d ago
News Placeholder
MNKD Stock Records Biggest Single-Day Gains In Over 5 Years, Breaches A Key Technical Milestone – What’s Driving This Rally?
MannKind is developing a dry powder inhalation version of a drug to treat pulmonary arterial hypertension.
Stocktwits·10d ago
News Placeholder
Biotech Stocks To Add to Your Watchlist - May 6th
Danaher, Avalo Therapeutics, Vertex Pharmaceuticals, United Therapeutics, argenex, ImmunityBio, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science and technology t...
MarketBeat·10d ago
News Placeholder
Transcript: United Therapeutics Q1 2026 Earnings Conference Call
read more...
Benzinga·10d ago
<
1
2
...
>

Latest UTHR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.